

Press release, January 29th, 2010

New number of shares and votes in Biovitrum AB (publ)

The total number of shares in Biovitrum AB (publ) as per January 29th, 2010 amounts to 210,041,139 shares, whereof 209,525,554 common shares and 515,585 class C shares¹, corresponding to in total 209,577,112.50 votes. The increase in the number of shares and votes results from a rights issue of 100,792,632 common shares and an issue in kind of 58,336,606 common shares to certain shareholders in Swedish Orphan International Holding AB as payment for a total of around 48 percent of the outstanding shares in Swedish Orphan International Holding AB.

For further information, please contact:

Göran Arvidson, CFO Biovitrum
Phone: +46 70 633 30 42

Erik Kinnman, EVP Investor Relations Biovitrum
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

About Swedish Orphan Biovitrum

On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish Orphan International Holding AB and created Swedish Orphan Biovitrum – a leading company focused on treatment of rare diseases.

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company with an international market presence. The company is focused on providing and developing orphan and niche specialist pharmaceuticals to patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line within rare diseases. Swedish Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: BVT) is listed on NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com.

The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 11:30 a.m CET on January 29th, 2010.

¹ All class C shares are held by Biovitrum.